AU4575799A - Creación de Inventos y Patentes con Inteligencia Artificial

AU4575799A – Fy7 polymerase
– Google Patents

AU4575799A – Fy7 polymerase
– Google Patents
Fy7 polymerase

Download PDF
Info

Publication number
AU4575799A

AU4575799A
AU45757/99A
AU4575799A
AU4575799A
AU 4575799 A
AU4575799 A
AU 4575799A
AU 45757/99 A
AU45757/99 A
AU 45757/99A
AU 4575799 A
AU4575799 A
AU 4575799A
AU 4575799 A
AU4575799 A
AU 4575799A
Authority
AU
Australia
Prior art keywords
dna
dna polymerase
polymerase
recombinant
sequencing
Prior art date
1998-06-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Application number
AU45757/99A
Other versions

AU768993B2
(en

Inventor
Maria Davis
Carl W Fuller
Lin Huang
Joseph A. Mamone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Global Life Sciences Solutions USA LLC

Original Assignee
GE Healthcare Bio Sciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1998-06-17
Filing date
1999-06-17
Publication date
2000-01-05

1999-06-17
Application filed by GE Healthcare Bio Sciences Corp
filed
Critical
GE Healthcare Bio Sciences Corp

2000-01-05
Publication of AU4575799A
publication
Critical
patent/AU4575799A/en

2002-05-23
Assigned to AMERSHAM BIOSCIENCES CORP.
reassignment
AMERSHAM BIOSCIENCES CORP.
Amend patent request/document other than specification (104)
Assignors: AMERSHAM PHARMACIA BIOTECH INC.

2004-01-15
Application granted
granted
Critical

2004-01-15
Publication of AU768993B2
publication
Critical
patent/AU768993B2/en

2006-08-17
Assigned to GE HEALTHCARE BIO-SCIENCES CORP.
reassignment
GE HEALTHCARE BIO-SCIENCES CORP.
Request to Amend Deed and Register
Assignors: AMERSHAM BIOSCIENCES CORP.

2019-06-17
Anticipated expiration
legal-status
Critical

Status
Ceased
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

108010014303
DNA-directed DNA polymerase
Proteins

0.000
claims
abstract
description
41

102000016928
DNA-directed DNA polymerase
Human genes

0.000
claims
abstract
description
41

230000000694
effects
Effects

0.000
claims
abstract
description
36

150000003839
salts
Chemical class

0.000
claims
abstract
description
23

108020004414
DNA
Proteins

0.000
claims
abstract
description
21

238000012163
sequencing technique
Methods

0.000
claims
abstract
description
17

239000002773
nucleotide
Substances

0.000
claims
abstract
description
13

125000003729
nucleotide group
Chemical group

0.000
claims
abstract
description
11

108020004707
nucleic acids
Proteins

0.000
claims
abstract
description
10

102000039446
nucleic acids
Human genes

0.000
claims
abstract
description
10

150000007523
nucleic acids
Chemical class

0.000
claims
abstract
description
10

238000000034
method
Methods

0.000
claims
abstract
description
7

108020004511
Recombinant DNA
Proteins

0.000
claims
abstract
description
5

241000588724
Escherichia coli
Species

0.000
claims
description
5

239000012634
fragment
Substances

0.000
claims
description
5

239000013612
plasmid
Substances

0.000
claims
description
5

-1
nucleotide triphosphates
Chemical class

0.000
claims
description
3

108700028369
Alleles
Proteins

0.000
claims
description
2

101100145155
Escherichia phage lambda cIII gene
Proteins

0.000
claims
description
2

239000003795
chemical substances by application
Substances

0.000
claims
description
2

239000001226
triphosphate
Substances

0.000
claims
description
2

235000011178
triphosphate
Nutrition

0.000
claims
description
2

125000003275
alpha amino acid group
Chemical group

0.000
claims
1

238000001712
DNA sequencing
Methods

0.000
description
18

108010058966
bacteriophage T7 induced DNA polymerase
Proteins

0.000
description
16

239000003153
chemical reaction reagent
Substances

0.000
description
13

238000006243
chemical reaction
Methods

0.000
description
12

239000000203
mixture
Substances

0.000
description
12

FAPWRFPIFSIZLT-UHFFFAOYSA-M
Sodium chloride
Chemical compound

[Na+].[Cl-]
FAPWRFPIFSIZLT-UHFFFAOYSA-M
0.000
description
10

102000004190
Enzymes
Human genes

0.000
description
9

108090000790
Enzymes
Proteins

0.000
description
9

LFQSCWFLJHTTHZ-UHFFFAOYSA-N
Ethanol
Chemical compound

CCO
LFQSCWFLJHTTHZ-UHFFFAOYSA-N
0.000
description
8

UFJPAQSLHAGEBL-RRKCRQDMSA-N
dITP
Chemical compound

O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(N=CNC2=O)=C2N=C1
UFJPAQSLHAGEBL-RRKCRQDMSA-N
0.000
description
7

PEDCQBHIVMGVHV-UHFFFAOYSA-N
Glycerine
Chemical compound

OCC(O)CO
PEDCQBHIVMGVHV-UHFFFAOYSA-N
0.000
description
6

108091028043
Nucleic acid sequence
Proteins

0.000
description
6

KCXVZYZYPLLWCC-UHFFFAOYSA-N
EDTA
Chemical compound

OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O
KCXVZYZYPLLWCC-UHFFFAOYSA-N
0.000
description
5

108060002716
Exonuclease
Proteins

0.000
description
5

239000000872
buffer
Substances

0.000
description
5

102000013165
exonuclease
Human genes

0.000
description
5

239000011780
sodium chloride
Substances

0.000
description
5

239000000243
solution
Substances

0.000
description
5

QKNYBSVHEMOAJP-UHFFFAOYSA-N
2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride
Chemical compound

Cl.OCC(N)(CO)CO
QKNYBSVHEMOAJP-UHFFFAOYSA-N
0.000
description
4

ZHNUHDYFZUAESO-UHFFFAOYSA-N
Formamide
Chemical compound

NC=O
ZHNUHDYFZUAESO-UHFFFAOYSA-N
0.000
description
4

238000005119
centrifugation
Methods

0.000
description
4

230000003247
decreasing effect
Effects

0.000
description
4

238000009472
formulation
Methods

0.000
description
4

239000000047
product
Substances

0.000
description
4

XLYOFNOQVPJJNP-UHFFFAOYSA-N
water
Chemical compound

O
XLYOFNOQVPJJNP-UHFFFAOYSA-N
0.000
description
4

229920001213
Polysorbate 20
Polymers

0.000
description
3

150000001413
amino acids
Chemical group

0.000
description
3

230000001351
cycling effect
Effects

0.000
description
3

230000001627
detrimental effect
Effects

0.000
description
3

230000035772
mutation
Effects

0.000
description
3

239000008188
pellet
Substances

0.000
description
3

239000000256
polyoxyethylene sorbitan monolaurate
Substances

0.000
description
3

235000010486
polyoxyethylene sorbitan monolaurate
Nutrition

0.000
description
3

102220092089
rs876657865
Human genes

0.000
description
3

108010037497
3′-nucleotidase
Proteins

0.000
description
2

108020004705
Codon
Proteins

0.000
description
2

108010017826
DNA Polymerase I
Proteins

0.000
description
2

102000004594
DNA Polymerase I
Human genes

0.000
description
2

XKMLYUALXHKNFT-UUOKFMHZSA-N
Guanosine-5′-triphosphate
Chemical class

C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O
XKMLYUALXHKNFT-UUOKFMHZSA-N
0.000
description
2

OWXMKDGYPWMGEB-UHFFFAOYSA-N
HEPPS
Chemical compound

OCCN1CCN(CCCS(O)(=O)=O)CC1
OWXMKDGYPWMGEB-UHFFFAOYSA-N
0.000
description
2

HAEJPQIATWHALX-KQYNXXCUSA-N
ITP
Chemical compound

O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(N=CNC2=O)=C2N=C1
HAEJPQIATWHALX-KQYNXXCUSA-N
0.000
description
2

TWRXJAOTZQYOKJ-UHFFFAOYSA-L
Magnesium chloride
Chemical compound

[Mg+2].[Cl-].[Cl-]
TWRXJAOTZQYOKJ-UHFFFAOYSA-L
0.000
description
2

108010006785
Taq Polymerase
Proteins

0.000
description
2

101900178114
Thermoplasma acidophilum Inorganic pyrophosphatase
Proteins

0.000
description
2

241000589500
Thermus aquaticus
Species

0.000
description
2

150000007942
carboxylates
Chemical group

0.000
description
2

UHZZMRAGKVHANO-UHFFFAOYSA-M
chlormequat chloride
Chemical compound

[Cl-].C[N+](C)(C)CCCl
UHZZMRAGKVHANO-UHFFFAOYSA-M
0.000
description
2

SUYVUBYJARFZHO-RRKCRQDMSA-N
dATP
Chemical compound

C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1
SUYVUBYJARFZHO-RRKCRQDMSA-N
0.000
description
2

SUYVUBYJARFZHO-UHFFFAOYSA-N
dATP
Natural products

C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1
SUYVUBYJARFZHO-UHFFFAOYSA-N
0.000
description
2

RGWHQCVHVJXOKC-SHYZEUOFSA-J
dCTP(4-)
Chemical compound

O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1
RGWHQCVHVJXOKC-SHYZEUOFSA-J
0.000
description
2

HAAZLUGHYHWQIW-KVQBGUIXSA-N
dGTP
Chemical compound

C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1
HAAZLUGHYHWQIW-KVQBGUIXSA-N
0.000
description
2

NHVNXKFIZYSCEB-XLPZGREQSA-N
dTTP
Chemical compound

O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1
NHVNXKFIZYSCEB-XLPZGREQSA-N
0.000
description
2

239000008367
deionised water
Substances

0.000
description
2

229910021641
deionized water
Inorganic materials

0.000
description
2

238000002474
experimental method
Methods

0.000
description
2

230000015784
hyperosmotic salinity response
Effects

0.000
description
2

238000011534
incubation
Methods

0.000
description
2

239000012139
lysis buffer
Substances

0.000
description
2

102000004169
proteins and genes
Human genes

0.000
description
2

108090000623
proteins and genes
Proteins

0.000
description
2

108010068698
spleen exonuclease
Proteins

0.000
description
2

239000006228
supernatant
Substances

0.000
description
2

JVIPLYCGEZUBIO-UHFFFAOYSA-N
2-(4-fluorophenyl)-1,3-dioxoisoindole-5-carboxylic acid
Chemical compound

O=C1C2=CC(C(=O)O)=CC=C2C(=O)N1C1=CC=C(F)C=C1
JVIPLYCGEZUBIO-UHFFFAOYSA-N
0.000
description
1

SXGZJKUKBWWHRA-UHFFFAOYSA-N
2-(N-morpholiniumyl)ethanesulfonate
Chemical compound

[O-]S(=O)(=O)CC[NH+]1CCOCC1
SXGZJKUKBWWHRA-UHFFFAOYSA-N
0.000
description
1

USFZMSVCRYTOJT-UHFFFAOYSA-N
Ammonium acetate
Chemical compound

N.CC(O)=O
USFZMSVCRYTOJT-UHFFFAOYSA-N
0.000
description
1

239000005695
Ammonium acetate
Substances

0.000
description
1

101000909256
Caldicellulosiruptor bescii (strain ATCC BAA-1888 / DSM 6725 / Z-1320) DNA polymerase I
Proteins

0.000
description
1

108050009160
DNA polymerase 1
Proteins

0.000
description
1

229920001425
Diethylaminoethyl cellulose
Polymers

0.000
description
1

102000004533
Endonucleases
Human genes

0.000
description
1

108010042407
Endonucleases
Proteins

0.000
description
1

108010010803
Gelatin
Proteins

0.000
description
1

239000007996
HEPPS buffer
Substances

0.000
description
1

HTTJABKRGRZYRN-UHFFFAOYSA-N
Heparin
Chemical compound

OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1
HTTJABKRGRZYRN-UHFFFAOYSA-N
0.000
description
1

CKLJMWTZIZZHCS-REOHCLBHSA-N
L-aspartic acid
Chemical compound

OC(=O)[C@@H](N)CC(O)=O
CKLJMWTZIZZHCS-REOHCLBHSA-N
0.000
description
1

FEWJPZIEWOKRBE-XIXRPRMCSA-N
Mesotartaric acid
Chemical compound

OC(=O)[C@@H](O)[C@@H](O)C(O)=O
FEWJPZIEWOKRBE-XIXRPRMCSA-N
0.000
description
1

108091034117
Oligonucleotide
Proteins

0.000
description
1

101000902592
Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1) DNA polymerase
Proteins

0.000
description
1

229920002684
Sepharose
Polymers

0.000
description
1

VMHLLURERBWHNL-UHFFFAOYSA-M
Sodium acetate
Chemical compound

[Na+].CC([O-])=O
VMHLLURERBWHNL-UHFFFAOYSA-M
0.000
description
1

241000589499
Thermus thermophilus
Species

0.000
description
1

108010020713
Tth polymerase
Proteins

0.000
description
1

238000009825
accumulation
Methods

0.000
description
1

235000004279
alanine
Nutrition

0.000
description
1

235000001014
amino acid
Nutrition

0.000
description
1

229940043376
ammonium acetate
Drugs

0.000
description
1

235000019257
ammonium acetate
Nutrition

0.000
description
1

AVKUERGKIZMTKX-NJBDSQKTSA-N
ampicillin
Chemical compound

C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1
AVKUERGKIZMTKX-NJBDSQKTSA-N
0.000
description
1

229960000723
ampicillin
Drugs

0.000
description
1

230000003321
amplification
Effects

0.000
description
1

235000003704
aspartic acid
Nutrition

0.000
description
1

230000001580
bacterial effect
Effects

0.000
description
1

OQFSQFPPLPISGP-UHFFFAOYSA-N
beta-carboxyaspartic acid
Natural products

OC(=O)C(N)C(C(O)=O)C(O)=O
OQFSQFPPLPISGP-UHFFFAOYSA-N
0.000
description
1

229940041514
candida albicans extract
Drugs

0.000
description
1

239000013043
chemical agent
Substances

0.000
description
1

239000013065
commercial product
Substances

0.000
description
1

238000007906
compression
Methods

0.000
description
1

230000006835
compression
Effects

0.000
description
1

239000013078
crystal
Substances

0.000
description
1

230000009089
cytolysis
Effects

0.000
description
1

238000004925
denaturation
Methods

0.000
description
1

230000036425
denaturation
Effects

0.000
description
1

230000001419
dependent effect
Effects

0.000
description
1

238000006073
displacement reaction
Methods

0.000
description
1

229920000159
gelatin
Polymers

0.000
description
1

239000008273
gelatin
Substances

0.000
description
1

235000019322
gelatine
Nutrition

0.000
description
1

235000011852
gelatine desserts
Nutrition

0.000
description
1

229960002897
heparin
Drugs

0.000
description
1

229920000669
heparin
Polymers

0.000
description
1

230000001771
impaired effect
Effects

0.000
description
1

238000000338
in vitro
Methods

0.000
description
1

239000006166
lysate
Substances

0.000
description
1

229910001629
magnesium chloride
Inorganic materials

0.000
description
1

SQQMAOCOWKFBNP-UHFFFAOYSA-L
manganese(II) sulfate
Chemical compound

[Mn+2].[O-]S([O-])(=O)=O
SQQMAOCOWKFBNP-UHFFFAOYSA-L
0.000
description
1

229910000357
manganese(II) sulfate
Inorganic materials

0.000
description
1

238000010369
molecular cloning
Methods

0.000
description
1

238000002703
mutagenesis
Methods

0.000
description
1

231100000350
mutagenesis
Toxicity

0.000
description
1

231100000219
mutagenic
Toxicity

0.000
description
1

230000003505
mutagenic effect
Effects

0.000
description
1

MHWLWQUZZRMNGJ-UHFFFAOYSA-N
nalidixic acid
Chemical compound

C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1
MHWLWQUZZRMNGJ-UHFFFAOYSA-N
0.000
description
1

229960000210
nalidixic acid
Drugs

0.000
description
1

238000003199
nucleic acid amplification method
Methods

0.000
description
1

238000003752
polymerase chain reaction
Methods

0.000
description
1

238000002360
preparation method
Methods

0.000
description
1

235000018102
proteins
Nutrition

0.000
description
1

238000000746
purification
Methods

0.000
description
1

239000011541
reaction mixture
Substances

0.000
description
1

230000010076
replication
Effects

0.000
description
1

238000002741
site-directed mutagenesis
Methods

0.000
description
1

239000001632
sodium acetate
Substances

0.000
description
1

235000017281
sodium acetate
Nutrition

0.000
description
1

230000002459
sustained effect
Effects

0.000
description
1

230000009466
transformation
Effects

0.000
description
1

239000012137
tryptone
Substances

0.000
description
1

239000012138
yeast extract
Substances

0.000
description
1

Classifications

C—CHEMISTRY; METALLURGY

C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA

C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes

C12N9/10—Transferases (2.)

C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

C12N9/1241—Nucleotidyltransferases (2.7.7)

C12N9/1252—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase

C—CHEMISTRY; METALLURGY

C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

C12Y—ENZYMES

C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)

C12Y207/07—Nucleotidyltransferases (2.7.7)

C12Y207/07007—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase

Abstract

A purified recombinant thermostable DNA polymerase polymerase which exhibits at least about 80% activity at salt concentations of 50 mM and greater, at least about 70% activity at salt concentrations of 25 mM and greater, and having a processivity of about 30 nucleotides per binding event. An isolated nucleic acid that encodes the thermostable DNA polymerase, as well as a recombinant DNA vector comprising the nucleic acid and a recombinant host cell transformed with the vector, are also disclosed. A method of sequencing DNA using the DNA polymerase as well as a kit for sequencing DNA is also disclosed.

Description

WO 99/65938 PCT/US99/13741 FY7 POLYMERASE CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to United States Provisional Application Serial No. 60/089,556, filed on June 17, 1998, the entire disclosure of which is incorporated in its herein. BACKGROUND OF THE INVENTION Field of the Invention The instant disclosure pertains to thermostable DNA polymerases which exhibit improved robustness and efficiency. Background DNA polymerases are enzymes which are useful in many recombinant DNA techniques such as nucleic acid amplification by the polymerase chain reaction («PCR»), self sustained sequence replication («3SR»), and high temperature DNA sequencing. Thermostable polymerases are particularly useful. Because heat does not destroy the polymerase activity, there is no need to add additional polymerase after every denaturation step. However, many thermostable polymerases have been found to display a 5′ to 3′ exonuclease or structure-dependent single-stranded endonuclease («SDSSE») activity which may limit the amount of product produced or contribute to the plateau phenomenon in the normally exponential accumulation of product. Such 5′ to 3′ nuclease activity may contribute to an impaired ability to efficiently generate long PCR products greater than or equal to 10kb, particularly for G+C rich targets. In DNA sequencing applications and cycle sequencing applications, the presence of 5′ to 3′ nuclease activity may contribute to a reduction in desired band intensities and/or generation of spurious or background bands. Additionally, many of the enzymes presently available are sensitive to high salt environments, a condition commonly Presently available enzymes have so-so processing ability (are more distributive – fall off more often – explain in more detail) dITP added to address compression problems – usually kills activity of enzyme Thus, a need continues to exist for an improved DNA polymerase having increased tolerance to high salt conditions, efficient utilization of dITP, high productivity, and improved performance on GC-rich templates.
WO 99/65938 2 PCT/US99/13741 BRIEF SUMMARY OF THE INVENTION The instant disclosure teaches a purified recombinant thermostable DNA polymerase comprising the amino acid sequence set forth in Figure 1, as well as a purified recombinant thermostable DNA polymerase which exhibits at least about 80% activity at salt concentations of 50 mM and greater. The instant disclosure further teaches a purified recombinant thermostable DNA polymerase which exhibits at least about 70% activity at salt concentrations of 25 mM and greater, and a purified recombinant thermostable DNA polymerase having a processivity of about 30 nucleotides per binding event. The instant disclosure also teaches an isolated nucleic acid that encodes a thermostable DNA polymerase, wherein said nucleic acid consists of the nucleotide sequence set forth in Figure 1, as well as a recombinant DNA vector that comprises the nucleic acid, and a recombinant host cell transformed with the vector. The instant disclosure also teaches a method of sequencing DNA comprising the step of generating chain terminated fragments from the DNA template to be sequenced with the DNA polymerase in the presence of at least one chain terminating agent and one or more nucleotide triphosphates, and determining the sequence of said DNA from the sizes of said fragments. The instant disclosure also teaches a kit for sequencing DNA comprising the DNA polymerase. BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS FIGURE 1 depicts the amino acid sequence (and DNA sequence encoding therefor) for the FY7 polymerase. FIGURE 2 depicts the DNA sequence of M 13mp 18 DNA sequenced using the FY7 polymerase formulated in Mn conditions, as shown by a print out from an ABI model 377 automated fluorescent DNA sequencing apparatus. FIGURE 3 depicts the DNA sequence of M1 3mp 18 DNA sequenced using the FY7 polymerase formulated in Mg conditions, as shown by a print out from an ABI model 377 automated fluorescent DNA sequencing apparatus. FIGURE 4 depicts the percent of maximum polymerase activity for Thermo Sequenasem enzyme DNA polymerase versus FY7 DNA polymerase under varyingKCl concentrations.
WO 99/65938 3 PCTIUS99/13741 FIGURE 5 depicts the effect of high salt concentrations on DNA sequencing ability in radioactively labeled DNA sequencing reactions using Thermo SequenaseTM enzyme DNA polymerase versus FY7 DNA polymerase. FIGURES 6-10 depict the effect of increasing salt concentration on the performance of Thermo Sequenase. At concentrations as low as 25mM data quality is affected with the read length being decreased from at least 600 bases to about 450 bases. At 50mM salt the read length is further decreased to about 350 bases, 75mM to about 250 bases and at 100mM the read length is negligible. FIGURES 11-15 depict the effect of increasing salt concentration on the performance of FY7 DNA polymerase. There is no detrimental effect on performance to at least 75mM KCl and only a slight decrease in data quality at 100mM KCl. FIGURE 16 depicts the processivity measured for Thermo Sequenase DNA polymerase, AmpliTaq FS DNA polymerase, compared with the processivity measured for FY7 DNA polymerase. FIGURE 17 depicts the improved read length obtained when using FY7 polymerase versus Thermo Sequenase DNA polymerase in radioactively labeled sequencing reactions incorporating the dGTP (Guanosine triphosphate) analog dITP (Inosine triphosphate) at 72 «C. FIGURES 18-22 show the effect of increasing extension step time on the read length and data quality produced by Thermo Sequenase DNA polymerase in fluorescently labeled terminator DNA sequencing reactions FIGURES 23-27 show the effect of increasing extension step time on the read length and data quality produced by FY7 DNA polymerase in fluorescently labeled terminator DNA sequencing reactions. DETAILED DESCRIPTION OF THE INVENTION A series of polymerase mutants were constructed with the aim of obtaining an improved polymerase for DNA sequencing, by reducing the exonuclease activity found in full length Thermus thermophilus and Thermus aquaticus DNA polymerase I enzymes. Six conserved motifs (Gutman and Minton (1993) Nucleic Acids Research 21, 4406 – 4407) can be identified in the amino-terminal domain of pol I type polymerases, in which the 5′ to 3′ exonuclease activity has been shown to reside. Further, six carboxylate residues in these conserved regions have been shown in a crystal structure to be located at the active site of the exonuclease domain of Thermus aquaticus DNA pol I (Kim et al., (1995) Nature 376, 612 616). Point mutations were made by site-directed mutagenesis to carboxylates and other residues in three of six conserved motifs in Tth and Taq polymerases as follows: WO 99/65938 4 PCTIUS99/13741 Taq D18A, Taq T140V, Taq D142N/D144N. All of these have the mutation F667Y outside of the exonuclease domain. Tth D18A, Tth T141V, Tth D143N/D145N. All of these have the mutation F669Y outside of the exonuclease domain. All polymerases were evaluated for exonuclease activity, processivity, strand displacement, salt tolerance, thermostability, and sequencing quality. One FY7 polymerase, Tth D1 8A, F669Y, is described in further detail below. EXAMPLES Methods In vitro mutagenesis PCR was employed to introduce an aspartic acid to alanine amino acid change at codon 18 (D18A) of cloned full length F669Y Tth (plasmid pMR10). Mutagenic Primer 1 (CTGTTCGAACCCAAAGGCCGTGTCCTCCTGGTGGCCGGCCACCAC) spans nucleotides 19-60 of pMR10 including codon 18 and a BstBI restriction site. Oligonucleotide Primer 2 (GAGGCTGCCGAATTCCAGCCTCTC) spans an EcoRl site of pMR10. pMR10 was used as template DNA. The PCR product was digested with BstBI and EcoRI and ligated to two fragments of pMR10: a 5000 bp Kpnl/ BstBI and a 2057 bp EcoRI / KpnI, creating plasmid pMR12. Cells of E. coli strain DHlX* were used for primary transformation, and strain M5248 (X c1857) was used for protein expression, although any comparable pair of E. coli strains carrying the cI* and c1857 alleles could be utilized. Alternatively, any rec’ cI* strain could be induced by chemical agents such as nalidixic acid to produce the polymerase. Purification of Polvmerase M5248 containing plasmid pMR12 was grown in one liter of LB medium (1% tryptone, 0.5% yeast extract, 1% NaCi), preferably 2X LB medium, containing 100 mg/ml ampicillin at 30’C. When the OD 600 reached 1.0, the culture was induced at 42*C for 1.5 hours. The cultures were then cooled to <20 0 C and the cells harvested by centrifugation in a Sorvall RC-3B centrifuge at 5000 rpm at 4'C for 15 to 30 minutes. Harvested cells were stored at -80*C. The cell pellet was resuspended in 25 ml pre-warmed lysis buffer (50 mM Tris-HCI pH 8.0, 10 mM MgCl 2 , 16 mM (NH 4 ) 2 SO 4 , 1 mM EDTA, 0.1%, preferably 0.2% Tween 20, 0.1%, preferably 0.2% NP40). Preferably, the lysis buffer contains 300 mM NaCl. Resuspended cells were incubated at 75 - 85 0 C for 10-20 minutes, sonicated for 1 minute, and WO 99/65938 5 PCTIUS99/13741 cleared by centrifugation. The cleared lysate was passed through a 300 ml column of diethylaminoethyl cellulose (Whatman DE 52) equilibrated in buffer A (50mM Tris-HCl pH 8.0, 1mM EDTA, 0.1% Tween 20, 0.1% NP40) containing 100mM, preferably 300 mM NaCl. Fractions were assayed for polymerase activity, and those demonstrating peak polymerase activity were pooled, diluted to 50 mM NaCl with Buffer A, and loaded onto a heparin sepharose column (20 ml) equilibrated with 50 mM NaCl in buffer A. The polymerase was eluted from the column with a linear salt gradient from 50 mM to 700mM NaCl in buffer A. Fractions were assayed for polymerase activity, and those demonstrating peak activity were pooled and dialyzed against final buffer (20mM Tris-HCl pH8.5, 50 % (v/v) glycerol, 0.1mM EDTA, 0.5% Tween 20, 0.5% NP40, ImM DTT, 100mM KCl). The purified protein is designated FY7. The amino acid sequence (and DNA sequence encoding therefor) are presented in Figure 1. Bacterial Strains E. coli strains: DHIX* [gyrA96, recAl, relAl, endAl, thi-1, hsdR17, supE44, k']; M5248 [k (bio275, c1857, cIII+, N+, k (Hi))]. PCR Plasmid DNA from E coli DHIk2 (pMR10) was prepared by SDS alkaline lysis method (Sambrook et al., Molecular Cloning 2 "d Ed. Cold Spring Harbor Press, 1989). Reaction conditions were as follows: 10 mM Tris-HCl pH 8.3, 50 mM KCl, 1.5 mM MgC1 2 , 0.001% gelatin, luM each primer, 2.5U Taq polymerase, per 100 il reaction. Cycling conditions were 94'C 2 minutes, then 35 cycles of 94'C 30s, 55'C 30s, 72'C 3 minutes, followed by 72C for 7 minutes. Example 1 Formulation of the enzyme in Mn conditions In the following "pre-mix" protocol, all the reagents are contained in two solutions; reagent mix A and reagent mix B. Reagent Mix A The following reagents were combined to make 10 ml of reagent mix A: 2.5 ml 1 M HEPPS N-(2-hydroxyethyl) piperazine-N'-(3-propanesulfonic acid), pH 8.0 500 d I M tartaric acid, pH 8.0 50,000 units FY7 DNA polymerase 1 unit Thermoplasma acidophilum inorganic pyrophosphatase 100 pl 1 0 0 mM dATP 100 il 100 mM dTTP WO 99/65938 6 PCT/US99/13741 100 pl 100 mM dCTP 500 pl 100 mM dITP 9.375 tl 100 iM C-7-propargylamino-4-rhodamine-6-G-ddATP 90 p 100 pM C-5-propargylamino-4-rhodamine-X-ddCTP 6.75 pl 100 4M C-7-propargylamino-4-rhodamine- 11 0-ddGTP 165 pl 100 p.M C-5-propargylamino-4-tetramethylrhodamine-ddUTP 10 p150 mM EDTA 1 ml glycerol The volume was made up to 10,000 41 with deionized H 2 0. Reagent Mix B The following reagents were combined to make 10 ml of reagent mix B: 10 41 1 M MES 2-(N-morpholino)ethanesulfonic acid, pH 6.0 200 p1 1M MgCl2 75 il IM MnSO4 The volume was made up to 10,000 p1 with demonized H 2 0. Example 2: Use of the formulation from Example 1 Two (2) p1 reagent mix A, 2 pl reagent mix B, 200 ng M13mp18 DNA, 5 pmole of primer (M13 - 40 Forward 5'-GTTTTCCCAGTCACGACGTTGTA), and deionized water to a total volume of 20 [l were mixed together and subjected to 25 cycles of (95 'C 30 seconds, 60 C 1 minute) in a thermal cycler. After cycling, 4 [1 of a solution which contained 1.5 M sodium acetate, 250 mM EDTA was added. The solution was mixed and 4 volumes (100 4l) of ethanol added. The DNA was precipitated by incubation on ice for 15-20 minutes followed by centrifugation. The supernatant was removed and the pellet was washed with 70% ethanol, dried and resuspended in 4 p1 of formamide containing loading dye. The resuspended DNA was then run on an automated fluorescent DNA sequencing apparatus (ABI model 377 instrument). The print out from the machine of the DNA sequence is shown as Figure 2. Example 3 Formulation of the enzyme in Mg conditions In the following "pre-mix" protocol, all the reagents are contained in one solution. Sequencing premix The following reagents were combined to make 800 p1 of Sequencing premix 200 p1 of 500 mM Tris-HCl pH 9.5, 20 mM MgC 2 WO 99/65938 PCT/US99/13741 100 p1l 40 units/ptl FY7 DNA polymerase, 0.0008 units/4l Thermoplasma acidophilum inorganic pyrophosphatase 100 t1 10 mM dITP, 2 mM dATP, 2 mM dTTP. 2 mM dCTP 100 il 0.125 pM C-7-propargylamino-4-rhodamine-6-G-ddATP 100 tl 1.2 pLM C-5-propargylamino-4-rhodamine-X-ddCTP 100 il 0.09 pM C-7-propargylamino-4-rhodamine-1 1 0-ddGTP 100 p1 2.2 pM C-5-propargylamino-4-tetramethylrhodamine-ddUTP Example 4 Use of the formulation from example 3 Four (4) l of sequencing premix, 200 ng Ml3mpl8 DNA, 5 pmole of primer (M13 40 Forward 5'- GTTTTCCCAGTCACGACGTTGTA), and deionized water to a total volume of 20 l were mixed together and subjected to 25 cycles of (95 'C 30 seconds, 60 C 2 minutes) in a thermal cycler. After cycling, 7 41 of 7.5 M ammonium acetate was added. The solution was mixed and 4 volumes (100 p.l) of ethanol added. The DNA was precipitated by incubation on ice for 15-20 minutes followed by centrifugation. The supernatant was removed and the pellet was washed with 70% ethanol, dried and resuspended in 4 41 of formamide containing loading dye. The resuspended DNA was then run on an automated fluorescent DNA sequencing apparatus (ABI model 377 instrument). The print out from the machine of the DNA sequence is shown as Figure 3. Example 5 Polymerase Activity versus Salt Concentration (KCI) for Thermo Sequenase TM enzyme and FY7 enzyme. The percent of maximum polymerase activity was measured for Thermo SequenaseTM enzyme DNA polymerase and FY7 DNA polymerase under varyingKCI concentrations. The results are depicted in Figure 4. The data indicate that FY7 has a much higher salt optimum as well as broader range of tolerance for salt in the reaction mixture than Thermo Sequenase TM. The salt concentration which gives 50% activity is five-fold higher for FY7 than for Thermo Sequenase. The effect of high salt concentrations on DNA sequencing ability in radioactively labeled DNA sequencing reactions was also examined. The results are presented in Figure 5. At KCl concentrations of 50mM or higher Thermo SequenaseTM polymerase performance degrades to levels at which usable data cannot be extracted. FY7 DNA polymerase, however, is able to give quite good sequencing data at concentrations of KCl of 100mM. Example 6 Fluorescent Sequencing Salt Tolerance WO 99/65938 8 PCTIUS99/13741 These experiments examined the effect of the above-demonstrated polymerase activity in high salt concentrations on DNA sequencing ability in fluorescently labeled terminator DNA sequencing reactions. The results are presented in Figures 6-15. Figures 6-10 show the effect of increasing salt concentration on the performance of Thermo Sequenase. At concentrations as low as 25mM data quality is affected with the read length being decreased from at least 600 bases to about 450 bases. At 50mM salt the read length is further decreased to about 350 bases, 75mM to about 250 bases and at 100mM the read length is negligible. Figures 11-15 show the effect of increasing salt concentration on the performance of FY7 DNA polymerase. There is no detrimental effect on performance to at least 75mM KCl and only a slight decrease in data quality at 100mM KCl. As it is recognized that some types of DNA preparations may be contaminated with salt (which is detrimental to DNA sequencing data quality), the use of FY7 DNA polymerase allows for a more robust sequencing reaction over a broader range of template conditions. Example 7 Polymerase Processivity The processivity (number of nucleotides incorporated per DNA polymerase binding event) has been measured, for different DNA sequencing polymerases. The results are presented in Figure 16. Thermo Sequenase DNA polymerase has a processivity of only -4 nucleotides per binding event. AmpliTaq FS DNA polymerase has a processivity of -15 nucleotides per binding event. FY7 DNA polymerase has a processivity more than seven-fold greater than Thermo Sequenase DNA polymerase and -two-fold greater than AmpliTaq FS DNA polymerase at -30 nucleotides per binding event. Example 8 Polvmerase Extension with dITP at 72 C The series examined improved read length obtained when using FY7 polymerase versus Thermo Sequenase DNA polymerase in radioactively labeled sequencing reactions incorporating the dGTP (Guanosine triphosphate) analog dITP (Inosine triphosphate) at 72 *C. The results are presented in Figure 17. FY7 is able to incorporate >50-100 more nucleotides under standard 3 P[a-dATP sequencing conditions than Thermo Sequenase. Example 9 Effect of Extension Step Time on Length of Read These series of experiments examined the effect of increasing extension step time of the read length and data quality of Thermo Sequenase and FY7 DNA polymerases in fluorescently labeled terminator DNA sequencing reactions. The results are presented in Figures 18-27. Figures 18-22 show the effect of increasing extension step time on the read length and data quality produced by Thermo Sequenase DNA polymerase. This data shows that a minimum of a two WO 99/65938 9 PCT/US99/13741 minutes extension step is required by Thermo Sequenase in order to achieve a quality read of at least 600 bases. Signal strength generally increases to a maximum at a four minute extension (the time specified in the commercial product utilizing this enzyme and method). Figures 23-27 show the effect of increasing extension step time on the read length and data quality produced by FY7 DNA polymerase. This data shows that a minimum of a 30 second extension step is required by FY7 in order to achieve a quality read of at least 600 bases. Signal strengths plateau at about one minute extension time. The FY7 DNA polymerase can produce data of equivalent quality to Thermo Sequenase in one-quarter to one-half the time of extension reaction. Although the above examples describe various embodiments of the invention in detail, many variations will be apparent to those of ordinary skill in the art. Accordingly, the above examples are intended for illustration purposes and should not be used in any way to restrict the scope of the appended claims.

Claims (13)

1. A purified recombinant thermostable DNA polymerase comprising the amino acid sequence set forth in Figure 1.

2. A purified recombinant thermostable DNA polymerase which exhibits at least about 80% activity at salt concentations of 50 mM and greater.

3. A purified recombinant thermostable DNA polymerase which exhibits at least about 70% activity at salt concentrations of 25 mM and greater.

4. A purified recombinant thermostable DNA polymerase having a processivity of about 30 nucleotides per binding event.

5. An isolated nucleic acid that encodes a thermostable DNA polymerase, wherein said nucleic acid consists of the nucleotide sequence set forth in Figure 1

6. A recombinant DNA vector that comprises the nucleic acid of Claim 3.

7. The recombinant DNA sequence of Claim 4 comprising the plasmid pMR10.

8. A recombinant host cell transformed with the vector of Claim 5.

9. The recombinant host cell of Claim 6 that is E. coli.

10. The recombinant host cell of Claim 7 which is E. coli carrying the cI* and c1857 alleles.

11. The recombinant host cell of Claim 7 selected from the group consisting of DHIk’ [gyrA96, recAl, relAl, endAl, thi-1, hsdR17, supE44, k’] and M5248 [k (bio275. c1857, cIII+, N+, k (HI))].

12. Method of sequencing DNA comprising the step of generating chain terminated fragments from the DNA template to be sequenced with the DNA polymerase of Claim 1 in the presence of at least one chain terminating agent and one or more nucleotide triphosphates, and determining the sequence of said DNA from the sizes of said fragments. WO 99/65938 1 PCT/US99/13741

13. A kit for sequencing DNA comprising the DNA polymerase of Claim 1.

AU45757/99A
1998-06-17
1999-06-17
FY7 polymerase

Ceased

AU768993B2
(en)

Applications Claiming Priority (3)

Application Number
Priority Date
Filing Date
Title

US8955698P

1998-06-17
1998-06-17

US60/089556

1998-06-17

PCT/US1999/013741

WO1999065938A2
(en)

1998-06-17
1999-06-17
Fy7 polymerase

Publications (2)

Publication Number
Publication Date

AU4575799A
true

AU4575799A
(en)

2000-01-05

AU768993B2

AU768993B2
(en)

2004-01-15

Family
ID=22218300
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

AU45757/99A
Ceased

AU768993B2
(en)

1998-06-17
1999-06-17
FY7 polymerase

Country Status (9)

Country
Link

US
(1)

US6479267B1
(en)

EP
(1)

EP1086209B1
(en)

JP
(1)

JP4349545B2
(en)

CN
(1)

CN1134538C
(en)

AT
(1)

ATE371022T1
(en)

AU
(1)

AU768993B2
(en)

CA
(1)

CA2330735C
(en)

DE
(1)

DE69936919T2
(en)

WO
(1)

WO1999065938A2
(en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US7875440B2
(en)

1998-05-01
2011-01-25
Arizona Board Of Regents
Method of determining the nucleotide sequence of oligonucleotides and DNA molecules

US6780591B2
(en)

1998-05-01
2004-08-24
Arizona Board Of Regents
Method of determining the nucleotide sequence of oligonucleotides and DNA molecules

AU2002316586A1
(en)

2001-07-06
2003-01-21
Amersham Biosciences Corp
Novel dna polymerases having amino acid substitutions and homologs thereof

AU2002347981A1
(en)

2001-11-07
2003-05-19
Applera Corporation
Universal nucleotides for nucleic acid analysis

US7169560B2
(en)

2003-11-12
2007-01-30
Helicos Biosciences Corporation
Short cycle methods for sequencing polynucleotides

CA2557177A1
(en)

2004-02-19
2005-09-01
Stephen Quake
Methods and kits for analyzing polynucleotide sequences

WO2005123957A2
(en)

2004-06-10
2005-12-29
Ge Healthcare Bio-Sciences Corp.
Method for nucleic acid analysis

US20080305142A1
(en)

2004-12-11
2008-12-11
Cytogenix, Inc.
Cell Free Biosynthesis of High-Quality Nucleic Acid and Uses Thereof

US7666593B2
(en)

2005-08-26
2010-02-23
Helicos Biosciences Corporation
Single molecule sequencing of captured nucleic acids

WO2014146781A1
(en)

2013-03-18
2014-09-25
Qiagen Gmbh
Stabilisation of biological samples

GB201721053D0
(en)

2017-12-15
2018-01-31
Univ I Tromsø – Norges Arktiske Univ
DNA polymerases

CN110093410A
(en)

2019-05-21
2019-08-06
通用生物系统（安徽）有限公司
A kind of DNA sequencing reaction reagent and preparation method thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US5795762A
(en)

1986-08-22
1998-08-18
Roche Molecular Systems, Inc.
5′ to 3′ exonuclease mutations of thermostable DNA polymerases

US5618711A
(en)

1986-08-22
1997-04-08
Hoffmann-La Roche Inc.
Recombinant expression vectors and purification methods for Thermus thermophilus DNA polymerase

JP2531246B2
(en)

1988-08-26
1996-09-04
東洋紡績株式会社

Thermostable DNA polymerase and method for producing the same

DE69032543T2
(en)

1989-12-22
1999-04-15
Hoffmann La Roche

RECOMBINANT EXPRESSION VECTORS AND CLEANING METHOD FOR DNA POLYMERASE FROM THERMUS THERMOPHILUS

US5210015A
(en)

1990-08-06
1993-05-11
Hoffman-La Roche Inc.
Homogeneous assay system using the nuclease activity of a nucleic acid polymerase

US5593840A
(en)

1993-01-27
1997-01-14
Oncor, Inc.
Amplification of nucleic acid sequences

US5610066A
(en)

1993-12-10
1997-03-11
Amersham Life Science, Inc.
Nucleic acid modifying proteins from Pyrococcus furiosus

WO1995030756A1
(en)

1994-04-18
1995-11-16
United States Biochemical Corporation
Thermostable alkaline phosphatase of thermus thermophilus

CA2222744C
(en)

1995-05-31
2008-03-25
Amersham Life Science, Inc.
Thermostable dna polymerases

EP0871775A4
(en)

1995-09-08
2002-07-31
Life Technologies Inc
Cloned dna polymerases from thermotoga and mutants thereof

ES2162132T3
(en)

1995-12-15
2001-12-16
Amersham Pharm Biotech Inc

THERMO-STABLE DNA POLYMERASE FROM THERMOANAEROBACTER THERMOHYDROSULFURICUS AND MUTANT ENZYMES, OF SUPPLIED EXONUCLEASE ACTIVITY SO OBTAINED.

US6294325B1
(en)

1996-07-05
2001-09-25
The Mount Sinai School Of Medicine Of The City University Of New York
Cloning and expression of thermostable multi genes and proteins and uses thereof

1999

1999-06-17
WO
PCT/US1999/013741
patent/WO1999065938A2/en
active
IP Right Grant

1999-06-17
US
US09/334,818
patent/US6479267B1/en
not_active
Expired – Lifetime

1999-06-17
CN
CNB998098124A
patent/CN1134538C/en
not_active
Expired – Fee Related

1999-06-17
CA
CA2330735A
patent/CA2330735C/en
not_active
Expired – Fee Related

1999-06-17
AT
AT99928766T
patent/ATE371022T1/en
not_active
IP Right Cessation

1999-06-17
JP
JP2000554763A
patent/JP4349545B2/en
not_active
Expired – Fee Related

1999-06-17
EP
EP99928766A
patent/EP1086209B1/en
not_active
Expired – Lifetime

1999-06-17
AU
AU45757/99A
patent/AU768993B2/en
not_active
Ceased

1999-06-17
DE
DE69936919T
patent/DE69936919T2/en
not_active
Expired – Lifetime

Also Published As

Publication number
Publication date

WO1999065938A3
(en)

2000-04-06

CA2330735C
(en)

2010-05-11

JP2002517997A
(en)

2002-06-25

DE69936919T2
(en)

2008-05-15

CA2330735A1
(en)

1999-12-23

CN1313893A
(en)

2001-09-19

CN1134538C
(en)

2004-01-14

DE69936919D1
(en)

2007-10-04

WO1999065938A9
(en)

2000-06-08

JP4349545B2
(en)

2009-10-21

US6479267B1
(en)

2002-11-12

EP1086209A2
(en)

2001-03-28

WO1999065938A2
(en)

1999-12-23

EP1086209B1
(en)

2007-08-22

AU768993B2
(en)

2004-01-15

ATE371022T1
(en)

2007-09-15

Información de contacto